KIT and thymus neoplasm: Thomas et al. evaluated sunitinib, which is an oral multi-kinase inhibitor, including activity against VEGFR, KIT, and PDGF, in a phase 2 study of patients with advanced thymic tumors who progressed after at least one previous platinum-containing chemotherapy regimen [21].